Suppr超能文献

α-葡萄糖苷酶抑制剂依米格列他(BAY o 1248)对健康志愿者蔗糖和淀粉诱导的血糖及激素反应的抑制作用。

Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers.

作者信息

Lembcke B, Fölsch U R, Gatzemeier W, Lücke B, Ebert R, Siegel E, Creutzfeldt W

机构信息

Department of Internal Medicine, University of Göttingen, FRG.

出版信息

Eur J Clin Pharmacol. 1991;41(6):561-7. doi: 10.1007/BF00314985.

Abstract

The absorbable deoxynojirimycin derivative emiglitate (BAY o 1248) is a potent competitive inhibitor of small intestinal alpha-glucosidases in man. In two similar randomized, placebo-controlled, double blind investigations, the efficacy, duration of action and tolerability of single doses of 10, 20 and 40 mg emiglitate have been assessed in healthy male volunteers after repeated sucrose or maize-starch loads at 08.00, 12.00 and 17.00 h. Even at the lowest dose used, emiglitate almost abolished the glycaemic (-88%) and hormonal responses after the first sucrose meal, simultaneously evoking significant hydrogen evolution (mean peak H2-concentration greater than 100 ppm), which was not related to the dose, and which induced unacceptable symptoms of carbohydrate malabsorption, i.e. at the dosages tested, the inhibition of glycaemic and hormonal responses was at the expense of intolerable gastrointestinal adverse effects. Flattening of postprandial responses of blood glucose, serum insulin and gastric inhibitory polypeptide was still apparent after a second sucrose load 4 h later, demonstrating long-lasting inhibition of alpha-glucosidase activity. After starch, the dose dependency of inhibition emerged more clearly than after sucrose, i.e. the reduction was less pronounced. However, emiglitate led to significant reduction of the glycaemic and hormonal rises after both the first and second starch meals. Symptoms of carbohydrate malabsorption were absent after 10 mg and were negligible with 20 mg or 40 mg emiglitate. Breath hydrogen concentration increased gradually, indicating slight but significant carbohydrate malabsorption after the highest dose of the alpha-glucosidase inhibitor. The results show that a single morning dose of 20-40 mg emiglitate might be useful in the control of postprandial hyperglycaemia after breakfast and lunch.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

可吸收的脱氧野尻霉素衍生物依米格列他(BAY o 1248)是人体小肠α-葡萄糖苷酶的强效竞争性抑制剂。在两项相似的随机、安慰剂对照、双盲研究中,于上午8点、12点和17点对健康男性志愿者重复给予蔗糖或玉米淀粉负荷后,评估了单剂量10毫克、20毫克和40毫克依米格列他的疗效、作用持续时间和耐受性。即使使用最低剂量,依米格列他几乎消除了首次蔗糖餐后的血糖反应(-88%)和激素反应,同时引发显著的氢气释放(平均峰值H2浓度大于100 ppm),这与剂量无关,并导致了不可接受的碳水化合物吸收不良症状,即在测试剂量下,血糖和激素反应的抑制是以难以忍受的胃肠道不良反应为代价的。4小时后第二次蔗糖负荷后,餐后血糖、血清胰岛素和胃抑制多肽反应的平缓仍很明显,表明α-葡萄糖苷酶活性受到持久抑制。淀粉负荷后,抑制作用的剂量依赖性比蔗糖负荷后更明显,即降低程度较小。然而,依米格列他导致首次和第二次淀粉餐后血糖和激素升高均显著降低。10毫克依米格列他后无碳水化合物吸收不良症状,20毫克或40毫克依米格列他时可忽略不计。呼气氢气浓度逐渐升高,表明在最高剂量的α-葡萄糖苷酶抑制剂后存在轻微但显著的碳水化合物吸收不良。结果表明,早晨单次服用20 - 40毫克依米格列他可能有助于控制早餐和午餐后的餐后高血糖。(摘要截选至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验